FOLLICULAR / MARGINAL ZONE LYMPHOMA INCMOR 0208-301

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients with Relapsed / Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Back To Clinical Trials NCI Database Entry